Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial-Reference-Cited by-同舟云学术

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

Published:2023-09-21 Issue:11 Volume:37 Page:2309-2313
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kubasch A. S.^ORCID,Peterlin P.,Cluzeau T.^ORCID,Götze K. S.,Sockel K.,Teipel R.,Jentzsch M.^ORCID,Attalah H.,Sebert M.,Chermat F.,Gloaguen S.,Puttrich M.,Cross M.^ORCID,Schneider M.^ORCID,Kayser S.,Schipp D.,Giagounidis A.,Tirado-Gonzalez I.,Descot A.,van de Loosdrecht A.^ORCID,Weigert A.,Metzeler K. H.^ORCID,Fenaux P.,Medyouf H.,Platzbecker U.^ORCID,Ades L.^ORCID

Funder

BerGenBio

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-023-02029-1.pdf

Reference15 articles.

1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32.

2. Komrokji RS. Treatment of higher-risk myelodysplastic syndromes after failure of hypomethylating agents. Clin Lymphoma Myeloma Leuk. 2015;15:S56–9.

3. Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 2013;122:2443–52.

4. Loges S, Heuser M, Chromik J, Vigil CE, Paschka P, Re F, et al. The combination of AXL inhibitor bemcentinib and low dose cytarabine is well tolerated and efficacious in elderly relapsed AML patients: update from the ongoing BGBC003 phase II trial (NCT02488408). Blood. 2020;136:14.

5. Tirado-Gonzalez I, Descot A, Soetopo D, Nevmerzhitskaya A, Schäffer A, Kur IM, et al. AXL inhibition in macrophages stimulates host-versus-leukemia immunity and eradicates naïve and treatment-resistant leukemia. Cancer Discov. 2021;11:2924–43.